CTTI Recommends New Vaccine Approaches
The Clinical Trials Transformation Initiative (CTTI) have released recommendations for hospital acquired and ventilator-associated bacterial pneumonia (HABP/VABP) as part of its antibacterial drug development program.
The Clinical Trials Transformation Initiative (CTTI) have released recommendations for hospital acquired and ventilator-associated bacterial pneumonia (HABP/VABP) as part of its antibacterial drug development program. The recommendations outline clinical trial approaches such as early enrollment strategies and streamlining the collection of safety data.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025